TIANEPTINE-RETAIL SALE PROHIB

Illinois HB3168 aims to ban the sale of tianeptine, a substance that is not approved for retail sale, starting January 1, 2026. The bill allows for exceptions for products that are legally prescribed by healthcare professionals. Violating this ban would result in a business offense with a fine of at least $1,500.

Supporters of HB3168 argue that this legislation is essential for public health and safety, as it addresses the potential risks associated with tianeptine use. They believe that by prohibiting its retail sale, the state can prevent misuse and protect vulnerable populations from harmful substances.

Critics of HB3168 may argue that the bill unnecessarily restricts access to a substance that could have legitimate therapeutic uses under professional guidance. They might claim that the legislation could limit options for patients who could benefit from tianeptine when prescribed by qualified healthcare providers.